Revolution Medicines Inc

Explore Mancini Anthony’s 10(b)(5)(1) trades at Revolution Medicines—buying and selling large blocks to gauge insider confidence and market timing.

Insider Mark Goldsmith’s bulk buys at under $5 per share signal confidence in Revolution Medicines’ oncology pipeline and $500 M raise, hinting at upside but urging cautious investment pending clinical milestones.

Insider sales by Revolution Medicines’ general counsel reveal routine 10(b)(5) trading, not a warning sign – investors can keep an eye on modest share‑rebalancing amid a still‑strong pipeline.

Insightful look at Margaret Horn’s March 2026 share sale, its tax‑withholding context, and how it reflects insider confidence in Revolution Medicines’ RAS pipeline.

Revolution Medicines insider sales are tax‑driven, not bearish, and fit historic patterns; focus on upcoming RAS(ON) trial data for real catalysts.

Revolution Medicines insider trades reveal a strategic shift—executives buy while one sells, signaling confidence in its oncology pipeline and potential undervaluation.

Insider buying boosts Revolution Medicines stock – Kelsey Michael’s 21k share purchase and options signal confidence, hinting at a rally as the oncology pipeline advances.

Insider buying surge at Revolution Medicines signals strong leadership confidence, suggesting potential upside as the oncology firm targets key clinical milestones.

Insightful look at Revolution Medicines’ COO Margaret Horn’s 10(b)(5)(1) trades shows a balanced buy‑low, sell‑high strategy that signals insider confidence in its oncology pipeline while managing liquidity.

Insight into COO Margaret Horn’s 10b5‑1 trades at Revolution Medicines and what it means for investors and the company’s future.